We hypothesize that the tumor’s immunophenotype and the patient’s complete and durable response to ICI might be the result of BAP1-deficiency, making BAP1 alterations a putative biomarker for response to immunotherapy in breast cancers that harbor them. The gene discussed is BAP1; the disease is breast carcinoma.